Adicet Bio, INC

Adicet Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Adicet Bio announced its first-quarter 2026 financial results, highlighting progress in its autoimmune and cancer cell therapy programs, with key clinical updates anticipated mid-year.

Adicet Bio, Inc. reports an exchange of common stock for a pre-funded warrant with RA Capital Management.

Adicet Bio announced its Q4 and full-year 2025 financial results, highlighting strong clinical progress in autoimmune and solid tumor programs and a solid cash position.

Adicet Bio announced significant progress in its autoimmune and oncology pipelines, including doubled patient enrollment for prula-cel and an extended cash runway into late 2027.

Adicet Bio, Inc. announced a 1-for-16 reverse stock split, effective December 30, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Adicet Bio reports on its Q2 2026 financial and operational progress, highlighting advancements in its gamma delta T cell therapies while managing ongoing operational expenses and cash reserves.

Adicet Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $20.2 million and providing updates on its gamma delta T cell therapies.

Adicet Bio, a clinical-stage biotechnology company, reported its Q3 2025 financial results, highlighted positive preliminary ADI-001 data in autoimmune diseases, and secured $74.8 million in a recent offering, while addressing Nasdaq listing compliance.

Adicet Bio, a clinical-stage biotechnology company, reported increased net losses and a strategic pipeline prioritization, including a 30% workforce reduction, to focus on its lead autoimmune and solid tumor programs.

Adicet Bio, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025 and provides an update on its clinical development programs.

Adicet Bio, a clinical-stage biotechnology company, released its Q3 2024 financial results, highlighting progress in its gamma delta T-cell therapy programs and providing updates on clinical trials.

Adicet Bio, Inc. has filed an amendment to its 2025 annual report (10-K/A) to update disclosures regarding its internal controls and procedures.

Adicet Bio reports positive preliminary Phase 1 results for prula-cel in autoimmune diseases, plans pivotal trials, and secures financing while facing substantial losses.

Adicet Bio advances clinical development of ADI-001 in autoimmune diseases and ADI-270 in renal cell carcinoma while reporting a net loss of $117.1 million for the year ended December 31, 2024.

Adicet Bio's 2023 10-K filing details progress in clinical trials for ADI-001 and ADI-270, along with plans for further development in autoimmune diseases and cancer.

Lloyd Klickstein, Chief Medical Officer and a Director of Adicet Bio, Inc., received 18,300 shares of common stock on August 5, 2026.

RA Capital Management, L.P. has reported a transaction involving the exchange of common stock for a pre-funded warrant in Adicet Bio, Inc.

RA Capital Management, L.P. has acquired significant shares in Adicet Bio, Inc. through multiple transactions between February 18-20, 2026.

OrbiMed Advisors LLC and affiliated entities have reported significant transactions involving Adicet Bio, Inc. (ACET) common stock.

Adicet Bio's Chief Financial Officer, Brian Nicholas Harvey, was granted 43,361 stock options with an exercise price of $6.81.

Adicet Bio's President & CEO, Schor Chen, was granted 468,555 stock options with a $6.81 exercise price, vesting monthly over four years.

Adicet Bio, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 17, 2026, with key proposals including director elections and executive compensation.

Adicet Bio, Inc. will hold a Special Meeting on December 19, 2025, to vote on a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Adicet Bio, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Adicet Bio announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.

Adicet Bio is asking stockholders to vote on several important proposals at its upcoming annual meeting, including increasing authorized shares and limiting officer liability.

Adicet Bio is holding its annual stockholder meeting on June 5, 2024, to vote on proposals including the election of directors, amendments to the stock option plan and corporate charter, executive compensation, and auditor ratification.

OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Adicet Bio, Inc. by over 1%, reporting a combined stake of 8.8% as of April 10, 2026.

OrbiMed entities updated their beneficial ownership in Adicet Bio, Inc. following a registered direct offering that increased the issuer's outstanding shares.

RA Capital Management and its affiliates report maintaining a 9.9% beneficial ownership in Adicet Bio, Inc. as of June 30, 2026, primarily through RA Capital Healthcare Fund, L.P.

Woodline Partners LP has disclosed beneficial ownership of 313,124 shares, representing 3.3% of Adicet Bio, Inc.'s common stock, as of March 31, 2026.

RA Capital Management, along with its affiliates, has reported beneficial ownership of 12.3% of Adicet Bio's common stock, totaling 1,182,624 shares, as of February 17, 2026.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported a 6.5% beneficial ownership stake in Adicet Bio, Inc. as of December 31, 2025.

Tang Capital Management, LLC and affiliated entities have filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Adicet Bio, Inc. as of March 31, 2025.